Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths

PURPOSE: A CDK4/6 inhibitor (CDK4/6i) combined with endocrine therapy is the standard of care for patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) metastatic breast cancer (MBC). However, the incorporation of these agents into clinical practice remains challenging. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinert, Tomás, Pellegrini, Rodrigo, Barrios, Carlos Henrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434502/
https://www.ncbi.nlm.nih.gov/pubmed/32863875
http://dx.doi.org/10.3332/ecancer.2020.1081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434502/
https://www.ncbi.nlm.nih.gov/pubmed/32863875
http://dx.doi.org/10.3332/ecancer.2020.1081

Ejemplares similares